Clinical Trial

Preventive Dendritic Cell Vaccination for Lynch Syndrome

Study acronym: PREVENT-Lynch
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The aim of this study is to assess safety, feasibility and immunogenicity of vaccination with neopeptide-loaded dendritic cells in Lynch Syndrome subjects who are known to be carrier of a germline MMR-gene mutation without signs of disease.
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-05-07
notable Enrollment reduced: 23 -> 13 participants 2026-05-07
Trial Details
NCT Number NCT07412197
Lead Sponsor Radboud University Medical Center
Collaborators: Dutch Cancer Society
Conditions Lynch Syndrome
Enrollment 13 participants
Start Date 2026-08
Primary Completion 2029-12 (estimated)
Study Completion 2036-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-06